European medicines agency's emergency task force has initiated the review of veru's sabizabulin treatment for hospitalized covid-19 patients for emergency use in european union countries

Miami, july 27, 2022 (globe newswire) -- veru inc. (nasdaq: veru), a biopharmaceutical company focused on developing novel medicines for covid-19 and other viral and ards-related diseases and for the management of breast and prostate cancers, today announced that the european medicines agency's (ema) emergency task force (etf) has informed the company that it has initiated the review of sabizabulin for the treatment of hospitalized covid-19 patients at high risk for acute respiratory distress syndrome (ards).
VERU Ratings Summary
VERU Quant Ranking